Doxorubicin hydrochloride is under clinical development by Skinject and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell ...

(Photo: Company Website) Pharma major Lupin Limited on Friday announced the launch of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials ...

Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials is a generic equivalent of Doxil (Liposomal), of Baxter Healthcare Corporation ...

Generic Doxil is indicated for the treatment of ovarian cancer, acquired immune deficiency syndrome-related Kaposi’s Sarcoma and multiple myeloma. Lupin is launching doxorubicin hydrochloride ...

Lupin Ltd. launched a generic cancer treatment drug in the US market on Wednesday. The firm launched Doxorubicin Hydrochloride Liposome Injection in single-dose vials in the US drug market. The drug ...

Lupin has launched a generic version of Doxorubicin Hydrochloride Liposome Injection (Doxil) in the US market, treating ovarian cancer, AIDS-related Kaposi's Sarcoma, and multiple myeloma. New Delhi, ...

Global pharma major Lupin Limited (Lupin) announced the launch of doxorubicin hydrochloride liposome injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials in the United States, ...